Search Results - "Shen Loo, Li"

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials by Montalban, Xavier, Vermersch, Patrick, Arnold, Douglas L, Bar-Or, Amit, Cree, Bruce A C, Cross, Anne H, Kubala Havrdova, Eva, Kappos, Ludwig, Stuve, Olaf, Wiendl, Heinz, Wolinsky, Jerry S, Dahlke, Frank, Le Bolay, Claire, Shen Loo, Li, Gopalakrishnan, Sathej, Hyvert, Yann, Javor, Andrija, Guehring, Hans, Tenenbaum, Nadia, Tomic, Davorka

“…Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here,…”
Get full text

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study by Lipton, Richard B., Lombard, Louise, Ruff, Dustin D., Krege, John H., Loo, Li Shen, Buchanan, Andrew, Melby, Thomas E., Buse, Dawn C.

“…Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT 1F receptor agonist…”
Get full text

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials by Loo, Li Shen, Ailani, Jessica, Schim, Jack, Baygani, Simin, Hundemer, Hans-Peter, Port, Martha, Krege, John H.

“…Objective To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications. Background While…”
Get full text

A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN by Lipton, Richard B., Baygani, Simin K., Tepper, Stewart J., Krege, John H., Vasudeva, Raghavendra, Pearlman, Eric M., Hauck, Paula M., Loo, Li Shen

“…Background While pain freedom at 2 h is a key primary outcome for current trials for acute treatment of migraine, the relationship between the degree of head…”
Get full text

Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide by Tang, Cheng Cai, Lim, Jean, Loo, Li Shen, Jung, Heike, Konig, Manige, Tham, Lai San

“…Dulaglutide 3.0 and 4.5 mg weekly doses were approved for additional glycemic control in adult patients with type 2 diabetes inadequately controlled with…”
Get full text

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study by Wilbraham, Darren, Berg, Paul H., Tsai, Max, Liffick, Emily, Loo, Li Shen, Doty, Erin Gautier, Sellers, Edward

“…Lasmiditan is a centrally penetrant, highly selective 5‐hydroxytryptamine (serotonin) receptor 1F (5HT1F) agonist under development as a novel therapy for…”
Get full text

An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma by Chakraborty, Sayan, Lakshmanan, Manikandan, Swa, Hannah L.F., Chen, Jianxiang, Zhang, Xiaoqian, Ong, Yan Shan, Loo, Li Shen, Akıncılar, Semih Can, Gunaratne, Jayantha, Tergaonkar, Vinay, Hui, Kam M., Hong, Wanjin

“…Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally. The identity and role of cell surface molecules driving complex…”
Get full text

TEADs Mediate Nuclear Retention of TAZ to Promote Oncogenic Transformation by Chan, Siew Wee, Lim, Chun Jye, Loo, Li Shen, Chong, Yaan Fun, Huang, Caixia, Hong, Wanjin

“…The transcriptional coactivators YAP and TAZ are downstream targets inhibited by the Hippo tumor suppressor pathway. The expression level of TAZ is recently…”
Get full text

A role for sorting nexin 27 in AMPA receptor trafficking by Loo, Li Shen, Tang, Ning, Al-Haddawi, Muthafar, Stewart Dawe, Gavin, Hong, Wanjin

“…Sorting nexin 27 (SNX27), a PDZ domain-containing endosomal protein, was recently shown to modulate glutamate receptor recycling in Down’s syndrome. However,…”
Get full text

Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down's syndrome by Wang, Xin, Zhao, Yingjun, Zhang, Xiaofei, Badie, Hedieh, Zhou, Ying, Mu, Yangling, Loo, Li Shen, Cai, Lei, Thompson, Robert C, Yang, Bo, Chen, Yaomin, Johnson, Peter F, Wu, Chengbiao, Bu, Guojun, Mobley, William C, Zhang, Dongxian, Gage, Fred H, Ranscht, Barbara, Zhang, Yun-wu, Lipton, Stuart A, Hong, Wanjin, Xu, Huaxi

“…Synaptic abnormalities and learning dysfunction are prominent characteristics of Down's syndrome. Now Huaxi Xu and colleagues show that expression of the…”
Get full text

Impaired Volume Regulation is the Mechanism of Excitotoxic Sensitization to Complement by Loo, Li Shen, McNamara, James O

“…Previous work demonstrated that a brief, sublethal excitotoxic insult strikingly increased the sensitivity of cortical neurons to the cytotoxic effects of the…”
Get full text

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial by Franek, Edward, Gerstein, Hertzel C., Riddle, Matthew C., Nicolay, Claudia, Hickey, Ana, Botros, Fady T., Loo, Li Shen

“…Aim To assess cardiovascular, glycaemic, weight and safety outcomes of long‐term treatment with dulaglutide 1.5 mg compared with placebo in patients with a…”
Get full text

Deficiency of Sorting Nexin 27 (SNX27) Leads to Growth Retardation and Elevated Levels of N-Methyl-d-Aspartate Receptor 2C (NR2C) by Cai, Lei, Loo, Li Shen, Atlashkin, Vadim, Hanson, Brendon J., Hong, Wanjin

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN) by Loo, Li Shen, Plato, Brian M, Turner, Ira M, Case, Michael G, Raskin, Joel, Dowsett, Sherie A, Krege, John H

“…We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. SAMURAI and SPARTAN were double-blind, placebo-controlled…”
Get full text

p125A exists as part of the mammalian Sec13/Sec31 COPII subcomplex to facilitate ER-Golgi transport by Ong, Yan Shan, Tang, Bor Luen, Loo, Li Shen, Hong, Wanjin

“…Coat protein II (COPII)-mediated export from the endoplasmic reticulum (ER) involves sequential recruitment of COPII complex components, including the Sar1…”
Get full text

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Knievel, Kerry, Buchanan, Andrew S, Lombard, Louise, Baygani, Simin, Raskin, Joel, Krege, John H, Loo, Li Shen, Komori, Mika, Tobin, Joshua

“…Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed…”
Get more information

Trajectory of migraine-related disability over 12 months with lasmiditan for acute treatment of migraine in the GLADIATOR Study (604) by Loo, Li Shen, Buse, Dawn, Lombard, Louise, Ruff, Dustin, Krege, John, Buchanan, Andy, Lipton, Richard

“…Abstract only…”
Get full text

Imaging synaptic inhibition in transgenic mice expressing the chloride indicator, Clomeleon by Berglund, Ken, Schleich, Wolfram, Krieger, Patrik, Loo, Li Shen, Wang, Dongqing, Cant, Nell B., Feng, Guoping, Augustine, George J., Kuner, Thomas

Get full text

642-P: A Model-Based Evaluation of Nausea and Vomiting Events for Additional Doses of Dulaglutide in Existing and Dulaglutide-Naïve Patients with Type 2 Diabetes by THAM, LAI-SAN, LIM, JEAN S.K., TANG, CHENG CAI, JUNG, HEIKE, KONIG, MANIGE, LOO, LI SHEN

“…Dulaglutide (DU) 3 mg and 4.5 mg once weekly (QW) doses were recently approved for additional glycemic control in adult patients with type 2 diabetes. If…”
Get full text

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review by Leroux, Elizabeth, Buchanan, Andrew, Lombard, Louise, Loo, Li Shen, Bridge, Daisy, Rousseau, Ben, Hopwood, Natasha, Matthews, Brandy R., Reuter, Uwe

“…Introduction Use of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30–40% of people. We…”
Get full text